80 search results for: expert insights
ADVENT Forum 2025 Event Page
From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
ADVENT Forum 2025 On Demand page
Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.
Charting the Future: Preventing the Atopic March
In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses how moderate-to-severe AD may hinder growth in pediatric patients and highlights data showing treatment with dupilumab may increase vertical growth in children of lower stature.
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews a Japanese study showing that early proactive treatment of infant atopic dermatitis with topical corticosteroids reduced the incidence of food allergy but was also associated with decreased gains in height and weight.
In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim describes the dynamic neuroimmune interactions in chronic pruritic skin diseases, emphasizing how type 2 cytokines and sensory nerves actively influence both itch perception and tissue inflammation.
From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.
Underlying Type 2 Inflammation Drives a Chronic Itch-Scratch Cycle in Atopic Dermatitis
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim explains how underlying type 2 inflammation sustains the chronic itch-scratch cycle in atopic dermatitis, highlighting the interplay of barrier dysfunction, cytokine signaling, and neuronal activation.
